Abstract
Issues linked to epileptic women are being reviewed. Ovarian steroid hormones have a number of effects on the brain that predispose to epileptic activity. In particular, estradiol produces changes in the hippocampus synapses predisposing hyperexcitability associated with seizures. Also, menses and menopause periods, in which there are changing levels of steroid ovarian hormones, are associated with a particular appearing of seizures (catamenial epilepsy) and with phenoptypic changes of previous ones. Epilepsy can affect the reproductive system, inducing endocrinal abnormalities (through disruption of cortical regulation of hypothalamus hormone release, and changes in the central nervous system concentration of steroid hormones induced by antiepileptics), infertility (linked to abnormalities in menstrual cycle or to the occurrence of polycytic ovaries, particularly in association with valproate treatment), and sexual disfunction (namely related to physiologic defects). Oral hormonal contraceptives should be performed using a pill with less than or equal to 50micro g of estrogen in order to prevent its potential loss of efficacy induced by enzyme-inducing antiepileptics. Concerning pregnancy, some topics should be discussed with, and advised to epileptic women, including the possibility of withdrawal antiepileptics and the need of folic acid supplementation when planning a pregnancy; the risk of increased seizure frequency during pregnancy, and of the occurrence of obstetric complications; the increased risk of teratogenesis associated with antiepileptic therapy (mainly if in polytheraphy) the need of vitamin K supplementation during the last month of pregnancy in order to avoid newborn haemorrhages and the general absence of risk of breastfeeding even under sustained antiepileptic therapy.
Keywords: Epileptic women, Catamenial epilepsy, Antiepileptics, Menstrual cycle, Polycytic ovaries, Valproate treatment, sexual disfunction, Vitamin K supplementation, Antiepileptic drugs, N methyl D aspartate, Central Nervous system, Gonodotrophin realizing hormone, Pituitary gonodothrophins follicle stimulating hormone, Infertilit, Hormonal Contraception, Teratogenesis, Follicle stimulating hormone, Luteinizing hormone, y aminobutyric acid, Cytochrome P450, Lamotrigine, Oral contraceptive, Neuronal tube defect
Current Pharmaceutical Design
Title: Current Issues on Epileptic Women
Volume: 6 Issue: 8
Author(s): Jose Pimentel
Affiliation:
Keywords: Epileptic women, Catamenial epilepsy, Antiepileptics, Menstrual cycle, Polycytic ovaries, Valproate treatment, sexual disfunction, Vitamin K supplementation, Antiepileptic drugs, N methyl D aspartate, Central Nervous system, Gonodotrophin realizing hormone, Pituitary gonodothrophins follicle stimulating hormone, Infertilit, Hormonal Contraception, Teratogenesis, Follicle stimulating hormone, Luteinizing hormone, y aminobutyric acid, Cytochrome P450, Lamotrigine, Oral contraceptive, Neuronal tube defect
Abstract: Issues linked to epileptic women are being reviewed. Ovarian steroid hormones have a number of effects on the brain that predispose to epileptic activity. In particular, estradiol produces changes in the hippocampus synapses predisposing hyperexcitability associated with seizures. Also, menses and menopause periods, in which there are changing levels of steroid ovarian hormones, are associated with a particular appearing of seizures (catamenial epilepsy) and with phenoptypic changes of previous ones. Epilepsy can affect the reproductive system, inducing endocrinal abnormalities (through disruption of cortical regulation of hypothalamus hormone release, and changes in the central nervous system concentration of steroid hormones induced by antiepileptics), infertility (linked to abnormalities in menstrual cycle or to the occurrence of polycytic ovaries, particularly in association with valproate treatment), and sexual disfunction (namely related to physiologic defects). Oral hormonal contraceptives should be performed using a pill with less than or equal to 50micro g of estrogen in order to prevent its potential loss of efficacy induced by enzyme-inducing antiepileptics. Concerning pregnancy, some topics should be discussed with, and advised to epileptic women, including the possibility of withdrawal antiepileptics and the need of folic acid supplementation when planning a pregnancy; the risk of increased seizure frequency during pregnancy, and of the occurrence of obstetric complications; the increased risk of teratogenesis associated with antiepileptic therapy (mainly if in polytheraphy) the need of vitamin K supplementation during the last month of pregnancy in order to avoid newborn haemorrhages and the general absence of risk of breastfeeding even under sustained antiepileptic therapy.
Export Options
About this article
Cite this article as:
Pimentel Jose, Current Issues on Epileptic Women, Current Pharmaceutical Design 2000; 6 (8) . https://dx.doi.org/10.2174/1381612003400263
DOI https://dx.doi.org/10.2174/1381612003400263 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Analysis of Pharmacogenomic VIP Variants of ABCB1, VDR and TPMT Genes in an Ethnically Isolated Population from the North Caucasus Living in Jordan
Current Drug Metabolism Anti-Inflammatory Immunotherapy for Multiple Sclerosis/Experimental Autoimmune Encephalomyelitis (EAE) Disease
Current Medicinal Chemistry 3D Printing Technology in Pharmaceutical Manufacturing and Drug Delivery Application
Current Pharmaceutical Design Synthesis and Screening of Substituted Thiosemicarbazone Derivatives: An Approach towards Novel Anticonvulsant Search
Central Nervous System Agents in Medicinal Chemistry Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics Decreased ERp57 Expression in WAG/Rij Rats Thalamus and Cortex: Possible Correlation with Absence Epilepsy
Protein & Peptide Letters Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Cognitive Impairment and Mossy Fiber Sprouting in a Rat Model of Drug-resistant Epilepsy Induced by Lithium-pilocarpine
Current Neurovascular Research mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Design, Synthesis, Characterization, Molecular Docking, ADME Properties and <i>In Vivo</i> Antipsychotic Activity of Aripiprazole Related Drugs Candidates
Letters in Drug Design & Discovery Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets <i>Spinacia Oleracea</i>: Exploring the Therapeutic Potential in Persian Medicine and Modern Pharmacology
Current Drug Discovery Technologies Synaptic Plasticity, Dementia and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets